Cagrilintide is the one compound on this site whose approval decision is pending while the page is written. The dosing record is therefore unusually clean: two trial programmes, one dose carried forward, one application on file, and no label yet. This page reports those figures with their dates and converts them into syringe units for the two vial sizes the research market sells.
Cagrilintide is a long-acting amylin analogue from Novo Nordisk, given once weekly and studied on its own and in a fixed combination with semaglutide called CagriSema. Medibact's Cagrilintide guide covers the molecule, its half-life and its trial results in depth; this page stays with dosing figures. The dosage hub lists every compound's page.
What the sources state
| Source | Kind | Figure | Date read |
|---|---|---|---|
| DailyMed SPL search | Label search | Zero records; no approved product | 2026-09-18 |
| Novo Nordisk release, 2025-12-18 | Sponsor release | NDA filed with the FDA for CagriSema 2.4 mg/2.4 mg once weekly, on REDEFINE 1 and 2; review expected in 2026 | 2026-09-18 |
| Phase 2, NCT03856047 (706 participants, 26 weeks; results posted 2023-07-18) | Trial protocol | 0.3, 0.6, 1.2, 2.4, 4.5 mg once weekly; liraglutide 3.0 mg daily; placebo | 2026-09-18 |
| Lau et al., Lancet 2021 (PMID 34798060) | Trial publication | Escalation up to 6 weeks; weight reduction 6.0% to 10.8% vs 3.0% placebo; 4.5 mg 10.8% vs liraglutide 9.0% | 2026-09-18 |
| REDEFINE 1, NCT05567796 (3,400 enrolled, 68 weeks; active, not recruiting) | Trial protocol | Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly after 16-week escalation, then 52 weeks; monotherapy and placebo arms | 2026-09-18 |
| Garvey et al., NEJM 2025 (PMID 40544433) | Trial publication | -20.4% at week 68 vs -3.0% placebo; 3,417 randomised | 2026-09-18 |
| Davies et al., NEJM 2025 (PMID 40544432), REDEFINE 2 | Trial publication | -13.7% vs -3.4% at week 68; 1,206 participants with type 2 diabetes | 2026-09-18 |
| Vendor and calculator pages | Commonly cited | 0.25, 0.5, 1.0, 1.7, 2.4 mg in four-week steps; some charts to 4.5 mg | 2026-09-18 |
The trial rows agree: once weekly, 2.4 mg as the dose carried forward, 4.5 mg as the ceiling ever registered. The last row does not come from any of them. Its steps are the Wegovy label's semaglutide schedule with the compound's name substituted, which is worth knowing when the same chart appears on several pages at once.
Units per dose at each research-vial size
Research-market cagrilintide is supplied in 5 mg and 10 mg vials. The table takes each at 1, 2 and 3 mL of water, states the concentration, and converts the phase 2 doses into U-100 syringe units (100 units = 1 mL). A cell over 100 units does not fit one syringe at that concentration.
| Vial | Water added | Concentration | 300 mcg | 600 mcg | 1.2 mg | 2.4 mg | 4.5 mg |
|---|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 6 | 12 | 24 | 48 | 90 |
| 5 mg | 2 mL | 2.5 mg/mL | 12 | 24 | 48 | 96 | 180 (>1 syringe) |
| 5 mg | 3 mL | 1.67 mg/mL | 18 | 36 | 72 | 144 (>1 syringe) | 270 (>1 syringe) |
| 10 mg | 1 mL | 10 mg/mL | 3 | 6 | 12 | 24 | 45 |
| 10 mg | 2 mL | 5 mg/mL | 6 | 12 | 24 | 48 | 90 |
| 10 mg | 3 mL | 3.33 mg/mL | 9 | 18 | 36 | 72 | 135 (>1 syringe) |
Two rows are identical, the 5 mg vial at 1 mL and the 10 mg vial at 2 mL, because both are 5 mg/mL; what differs is how many 2.4 mg amounts each vial contains, which is two and four. The 10 mg vial at 1 mL puts the 300 mcg phase 2 starting dose at 3 units, a figure that sits between marks on a standard 1 mL syringe scale, which is the practical reason the more dilute rows exist. The cagrilintide calculator works any combination entered, and the cagrilintide reconstitution page covers the water volumes per vial size in full.
The combination changes the arithmetic
In REDEFINE 1 cagrilintide was given with semaglutide at 2.4 mg each, as a single product with a fixed ratio. A research reader reproducing that ratio from two separate vials is doing two calculations, not one, because the two compounds are in different vials at different concentrations. The site's blend calculator exists for that case, and semaglutide dosage reports the semaglutide figures on their own. Nothing here suggests combining anything; the point is that a combination figure quoted as one number describes a product that does not exist as a single research vial.
What the figures omit
Every trial figure came with a weekly interval and a stated escalation: up to 6 weeks in phase 2, 16 weeks for CagriSema in REDEFINE 1. Each came with a duration, 26 or 68 weeks, and a population selected by BMI or by type 2 diabetes. REDEFINE 1's headline figure belongs to the combination, not to cagrilintide alone; the Lancet paper's 10.8% belongs to 26 weeks of monotherapy. A research vial supplies none of those conditions, and the arithmetic above moves only the milligram figures. There is no label to set a maximum, an indication or an approved concentration, and until the FDA acts on the December 2025 application there will not be one.
Related pages
Semaglutide dosage reports the other half of CagriSema; tirzepatide dosage and retatrutide dosage cover the incretin compounds most often compared with it. The general mixing procedure is documented on medibact.com's how to reconstitute peptides page; the reconstitution chart on this site lists concentrations for every vial size the calculators cover.
The insulin syringe units how-to explains the U-100 and U-40 scales and how a milligram figure becomes a syringe reading.
What this page does not do
This page reports what the registry, two trial publications, one sponsor release and the public web state about cagrilintide dosing, each with its source and date, and converts the sourced figures into syringe units for two vial sizes. It does not recommend an amount, a step, a schedule or a combination, and the trial protocols are reported as what was done, not as a plan. The transposed chart that circulates is reported so that its origin can be checked, not endorsed.
Sources and dates
Opened 2026-09-18: the DailyMed SPL search for cagrilintide (zero records); NCT03856047 and NCT05567796 on ClinicalTrials.gov; PMID 34798060 (Lau et al., Lancet 2021), PMID 40544433 (Garvey et al., NEJM 2025) and PMID 40544432 (Davies et al., NEJM 2025); Novo Nordisk's release of 2025-12-18 as distributed by PR Newswire; and a read of vendor and calculator pages for the schedule in circulation. Corrections go to the contact page.